Healthcare

Philips Partnership Boosts 4DMedical’s Global Expansion

December 03, 2025 03:02 PM AEDT| By Team Kalkine Media

This article explores how 4DMedical (ASX:4DX) has broadened its agreement with global technology group Philips to distribute its CT-based lung-imaging platform across North America.

Insider Moves and Market Shifts at Paragon Care (ASX:PGC)

December 03, 2025 10:52 AM AEDT| By Team Kalkine Media

This article explores the shifting dynamics at Paragon Care (ASX:PGC), focusing on insider activity, market response, and shareholder structure. It breaks down how different ownership groups influence decision-making and how the broader ASX stock mar...

Imugene (ASX:IMU) Advances CAR-T Therapy with 82% Response Rate

December 02, 2025 05:46 PM AEDT| By Team Kalkine Media

Imugene Ltd (ASX:IMU) continues to demonstrate progress in immuno-oncology with azer-cel, presenting meaningful developments in lymphoma treatment and expanding its footprint in the ASX stock market.

Unlocking PME Shares: Key Insights into Pro Medicus (ASX:PME)

December 02, 2025 05:37 PM AEDT| By Team Kalkine Media

Explore the essential insights into Pro Medicus Ltd (ASX:PME) shares, highlighting financial health, software innovations, and key metrics that shape performance in the ASX stock market. Learn what makes PME a notable presence in healthcare technolog...

Imugene Advances Azer-cel as Clinical Progress Gain Momentum

December 01, 2025 08:11 PM AEDT| By Team Kalkine Media

Imugene Ltd (ASX:IMU) continues to advance its immuno-oncology pipeline as its off-the-shelf CAR-T program azer-cel delivers encouraging results in people with varied forms of blood cancer. This update explores response outcomes, clinical expansion

CSL Ltd Continues to Lead Australia’s Healthcare Innovation

November 28, 2025 03:10 PM AEDT| By Team Kalkine Media

This article explores CSL Ltd (ASX:CSL), a major name in the global biotechnology landscape, focusing on its growth drivers, business structure, and position within the ASX stock market while avoiding any investment guidance terminology.

Insider Confidence in AdAlta (ASX:1AD) Sparks ASX Buzz

November 27, 2025 07:21 PM AEDT| By Team Kalkine Media

AdAlta (ASX:1AD) has caught attention due to increased insider involvement over the past year. This long-form article explores why insider ownership matters, what recent actions may signal about the company’s direction, and how the broader

Proteomics International: Cash Use & Growth Strategy (ASX:PIQ)

November 27, 2025 06:29 PM AEDT| By Team Kalkine Media

This article explores the cash usage and expansion strategies of Proteomics International Laboratories (ASX:PIQ), offering a clear look at how the biotechnology company navigates its funding needs while advancing research within Australia’s healthcar...

Unlocking Insights on CSL Ltd (ASX:CSL) Share Performance

November 27, 2025 05:43 PM AEDT| By Team Kalkine Media

Explore how CSL Ltd (ASX:CSL) continues to demonstrate steady growth in the ASX stock market, with a strong operational framework, revenue trends, and financial stability that make it a notable company for investors watching ASX dividend stocks.

Mesoblast (ASX:MSB) Outlook: Ryoncil Sales & Trial Update

November 27, 2025 05:38 PM AEDT| By Team Kalkine Media

Explore Mesoblast (ASX:MSB) valuation insights as Ryoncil revenue guidance and pivotal clinical trials spark market attention. Understand its market position, pipeline developments, and valuation context within the ASX stock market.

Imugene & JW Therapeutics Partner on CF33-CD19 for Tumors

November 27, 2025 04:47 PM AEDT| By Team Kalkine Media

Imugene (ASX:IMU) partners with JW Therapeutics to explore CF33-CD19 in combination with CD19 Car-T therapy for solid tumors, highlighting a novel "mark and kill" approach and advancing oncology innovation on the ASX stock market.

Breakthrough Immunotherapy in Focus: Imugene (ASX:IMU) on ASX 200

November 27, 2025 04:02 PM AEDT| By Sam

Imugene partners with JW Therapeutics to expand CAR-T therapy into solid tumours, aiming to transform oncology treatment with innovative virus-cell combination strategies impacting the ASX 200.

Recce Pharmaceuticals Expands IP Footprint in Hong Kong ASX 200 Update

November 27, 2025 03:58 PM AEDT| By Sam

Recce Pharmaceuticals (ASX:RCE) secures Hong Kong patent, advancing R327 and R529 anti-infectives with ongoing Phase 3 trials and expanded Asian IP footprint.

Proteomics International (ASX:PIQ) Cash Flow Overview

November 27, 2025 12:19 PM AEDT| By Team Kalkine Media

Explore how Proteomics International Laboratories (ASX:PIQ) manages its cash burn while investing in growth. Understand its cash runway, funding options, and operational resilience within the ASX stock market landscape.

Is Imricor Medical Systems (ASX:IMR) Navigating Debt Wisely?

November 27, 2025 12:06 PM AEDT| By Team Kalkine Media

This article explores the financial health of Imricor Medical Systems (ASX:IMR), focusing on its debt management, balance sheet strength, and growth outlook. It explains how the company’s current resources position it in the ASX stock market and what...

AdAlta (ASX:1AD) Insider Activity Shows Growing Confidence in Company Outlook

November 27, 2025 11:58 AM AEDT| By Team Kalkine Media

AdAlta (ASX:1AD) insiders have shown renewed confidence through increased shareholding, reflecting their commitment to the company’s long-term growth. Insider activity highlights trust in strategic direction despite market challenges.

Star Combo Pharma (ASX:S66): Key Business Moves Worth Watching

November 27, 2025 11:48 AM AEDT| By Team Kalkine Media

Star Combo Pharma (ASX:S66) is showing steady growth in earnings and revenue, supported by strong insider ownership and sound governance. This article explores its financial performance, market position, and why it remains an interesting company to m...